Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiracoxib vs indomethacin for acute flares of gout
2005-000229-51Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumiracoxib in gout (2 arms), sponsored by Novartis. Primary endpoint: Primary pain intensity endpoint. Started Apr 2005; status: completed.
02
Drugs
lumiracoxib
03
Conditions
gout
Beyond the preview
Go deeper on 2005-000229-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000229-51.